Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5271989
Max Phase: Preclinical
Molecular Formula: C22H19N5OS
Molecular Weight: 401.50
Associated Items:
ID: ALA5271989
Max Phase: Preclinical
Molecular Formula: C22H19N5OS
Molecular Weight: 401.50
Associated Items:
Canonical SMILES: CCc1ccccc1-n1nc(-c2c[nH]c3ccccc23)cc1/N=C1/NC(=O)CS1
Standard InChI: InChI=1S/C22H19N5OS/c1-2-14-7-3-6-10-19(14)27-20(24-22-25-21(28)13-29-22)11-18(26-27)16-12-23-17-9-5-4-8-15(16)17/h3-12,23H,2,13H2,1H3,(H,24,25,28)
Standard InChI Key: SGIQAELOXVQASQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 401.50 | Molecular Weight (Monoisotopic): 401.1310 | AlogP: 4.43 | #Rotatable Bonds: 4 |
Polar Surface Area: 75.07 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.57 | CX Basic pKa: 1.02 | CX LogP: 5.05 | CX LogD: 4.82 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.53 | Np Likeness Score: -0.90 |
1. Soni JP, Chilvery S, Sharma A, Reddy GN, Godugu C, Shankaraiah N.. (2023) Design, synthesis and in vitro cytotoxicity evaluation of indolo-pyrazoles grafted with thiazolidinone as tubulin polymerization inhibitors., 14 (3): [PMID:36970141] [10.1039/d2md00442a] |
Source(1):